37 related articles for article (PubMed ID: 18607795)
1. Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials.
Magirr D; Jaki T; Koenig F; Posch M
PLoS One; 2016; 11(2):e0146465. PubMed ID: 26863139
[TBL] [Abstract][Full Text] [Related]
2. Information-based group sequential design for post-market safety monitoring of medical products using real world data.
Zhang Z; Nielson C; Chuo CY; Ye Z
Pharm Stat; 2024 Apr; ():. PubMed ID: 38586914
[TBL] [Abstract][Full Text] [Related]
3. Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long-term endpoint: The non-Gaussian case.
Garcia Barrado L; Burzykowski T
Pharm Stat; 2024 Jun; ():. PubMed ID: 38837876
[TBL] [Abstract][Full Text] [Related]
4. Adaptive Multiple Comparison Sequential Design (AMCSD) for clinical trials.
Gao P; Li Y
J Biopharm Stat; 2024 May; 34(3):424-440. PubMed ID: 37526434
[TBL] [Abstract][Full Text] [Related]
5. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
6. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
7. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
Lachin JM
Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
[TBL] [Abstract][Full Text] [Related]
8. Stopping boundaries adjusted for sample size reestimation and negative stop.
Shun Z
J Biopharm Stat; 2002 Nov; 12(4):485-502. PubMed ID: 12477071
[TBL] [Abstract][Full Text] [Related]
9. Self-designing trial combined with classical group sequential monitoring.
Yin G; Shen Y
J Biopharm Stat; 2005; 15(4):667-75. PubMed ID: 16022171
[TBL] [Abstract][Full Text] [Related]
10. Accounting for interim safety monitoring of an adverse event upon termination of a clinical trial.
Dallas MJ
J Biopharm Stat; 2008; 18(4):631-8; discussion 439-45. PubMed ID: 18607795
[TBL] [Abstract][Full Text] [Related]
11. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
[TBL] [Abstract][Full Text] [Related]
12. Interim analyses and early termination of clinical trials.
Choi SC
J Biopharm Stat; 1997 Nov; 7(4):533-43. PubMed ID: 9358327
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
